and were given a second course of radiotherapy. The median follow-up period was 47.7 months (1.8 to 110.6) measured from the start of the reirradiation. IMRT of various types including conventional fractionation scheme, stereotactic radiotherapy, twice-daily (BID) radiation were used to deliver the second course of radiotherapy. The prescribed doses delivered from the different fractionation schemes were converted into Equivalent Dose at 2 Gy per fractions (EQD2) using a/b ratios of 10 Gy and 3 Gy for the disease and fatal complication respectively. The variations of the accrual local control and overall survival at 24 months versus the dose as well as the recurrent GTV volume were analyzed. The relationship between the fatal complication rate and the dose were also studied. Logistic regression was used to fit the dose and volume responses (if applicable) using a computer algorithm software. The significance of the responses were evaluated using the likelihood ratio test at a significance level of pZ0.05. Results: The dose delivered to the tumor ranged from 44.3 Gy to 72 Gy (EQD2). Local control and the rate of fatal complication appear to rise with the dose, but the relationships are not statistically significant (p Z 0.147 and pZ0.054 respectively). The overall survival rises with the dose until around 60 Gy (EQD2) and then falls again. The size of GTV varied significantly from 1.8 cc to 194 cc. The local control shows a significant decreasing trend with GTV volume (p<0.001). A similar trend can be seen on overall survival but has not reached statistical significance (pZ0.061). There is no clear trend or correlation between the fatal complication rate and the GTV volume. A multi-dimensional logistic model was also fitted to the local control versus the target dose and GTV volume. The result suggests that the local control is predominantly affected by the GTV volume as expected from the individual analyses. While local control also has an increasing trend with prescribed dose for smaller GTV, higher prescribed dose does not lead to higher control for large tumors, probably due to both the large tumor mass and the resulting deterioration of dose coverage in a recurrent radiotherapy setting. Conclusion: The GTV volume plays a significant role in the local control of the recurrent diseases. 60 Gy (EQD2) appears to be the optimal dose for achieving the best survival outcome while balancing the probability of local control and fatal complication, but a higher personalized dose based on the multi-dimensional logistic model might be considered for smaller tumors.
This meta-analysis was conducted to evaluate the association of CD133 and Nestin with epithelial ovarian cancer. Databases (PubMed, EMBASE, Web of Science, China National Knowledge Infrastructure, Wanfang) were searched for relevant studies updated in August 2017. CD133 and Nestin expression were estimated by immunohistochemistry. Statistical analysis was performed by RevMan. A total of 18 studies were included in this meta-analysis. High expression of both CD133 and Nestin was associated with late International Federation of Gynecology and Obstetrics stage (p < 0.00001), larger size of residual cancer (p < 0.05). CD133 overexpression was also associated with higher histological grade (p = 0.0006) and lymph node metastases (p < 0.00001). Nestin overexpression was associated with a higher rate of treatment resistance (p = 0.0007). Positive expression of CD133 and Nestin may be associated with aggressive biological behaviors in epithelial ovarian cancer.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.